MXCT MAXCYTE, INC.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1287098 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.1%
TTM net income YoY38.7%
TTM EPS YoY39.5%
Revenue 3-yr CAGR-3.3%
Net income 3-yr CAGR—
Margins
Gross margin81.0%
Operating margin-98.0%
Net margin-81.4%
FCF margin-62.4%
EBITDA margin-86.5%
Returns
ROE-16.9%
ROA-14.1%
ROIC (approx.)-17.5%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets17.3%
Debt / equity0.00x
Current ratio7.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-3.5%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $33.03M | $38.63M | $41.29M | $44.26M | $33.89M |
| Cost of revenue | $6.22M | $7.10M | $4.74M | $5.10M | $3.65M |
| Gross profit | $26.80M | $31.53M | $36.55M | $39.16M | $30.25M |
| R&D expense | $20.82M | $22.23M | $23.82M | $19.51M | $15.41M |
| SG&A expense | $28.12M | $29.69M | $30.07M | $25.83M | $18.68M |
| Operating income | -$51.90M | -$51.20M | -$48.30M | -$27.36M | -$18.19M |
| Interest expense | — | — | — | — | $5,400 |
| Pretax income | -$44.63M | -$41.05M | -$37.92M | — | — |
| Income tax | — | — | — | — | $0 |
| Net income | -$44.63M | -$41.05M | -$37.92M | -$23.57M | -$19.08M |
| EBITDA | -$47.56M | -$46.88M | -$44.13M | -$24.66M | -$16.76M |
| EPS (basic) | -0.42 | -0.39 | -0.37 | -0.23 | -0.21 |
| EPS (diluted) | -0.42 | -0.39 | -0.37 | -0.23 | -0.21 |
| Weighted avg. shares (diluted) | 106.43M | 104.85M | 103.27M | 101.70M | 90.62M |
| Balance sheet | |||||
| Cash & equivalents | $20.07M | $27.88M | $46.51M | $11.06M | $47.78M |
| Short-term investments | $82.98M | $126.60M | $121.78M | $216.28M | $207.26M |
| Receivables | $3.50M | $4.68M | $5.78M | $11.18M | $6.88M |
| Inventory | $7.55M | $8.91M | $12.23M | $8.58M | $5.20M |
| Current assets | $118.37M | $171.68M | $190.19M | $252.27M | $270.43M |
| PP&E, net | $17.53M | $19.71M | $23.51M | $23.73M | $7.68M |
| Intangibles | $650,000 | — | — | — | — |
| Total assets | $202.51M | $239.47M | $268.27M | $286.65M | $284.12M |
| Current liabilities | $14.27M | $15.78M | $17.86M | $15.43M | $15.62M |
| Total liabilities | $31.02M | $33.22M | $36.11M | $32.69M | $21.22M |
| Shareholders' equity | $171.49M | $206.25M | $232.17M | $253.97M | $262.90M |
| Shares outstanding | 106.79M | 105.71M | 103.96M | 102.40M | 101.20M |
| Cash flow statement | |||||
| Operating cash flow | -$34.41M | -$27.61M | -$21.69M | -$14.78M | -$10.68M |
| Capital expenditure | $1.77M | $1.65M | $3.70M | $18.48M | $3.83M |
| Free cash flow | -$36.18M | -$29.26M | -$25.39M | -$33.26M | -$14.51M |
| Investing cash flow | $25.93M | $6.93M | $54.98M | -$24.82M | -$195.01M |
| Financing cash flow | $656,000 | $2.06M | $2.14M | $2.89M | $234.72M |
| Depreciation & amortization | $4.34M | $4.32M | $4.17M | $2.70M | $1.42M |
| Stock-based compensation | $9.21M | $13.08M | $13.98M | $11.75M | $7.96M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.